CUSP06 is a CDH6-directed ADC with a differentiated profile and potentially best-in-class activity CUSP06 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor ADCs Promising signs of efficacy were observed in patients with heavily pretreated platinum-resistant...
Read More Details
Finally We wish PressBee provided you with enough information of ( OnCusp Therapeutics Announces Encouraging Initial Phase 1a Results from Ongoing First-in-Human Study Evaluating its CDH6-Directed Antibody-Drug Conjugate, CUSP06, in Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumo )
Also on site :
- Exactly How Many Times a Week To Walk To Improve Your Heart Health, According to Cardiologists
- Los Angeles unrest: Is Trump allowed to deploy National Guard troops?
- Olivia Rodrigo Sends Fans Into ‘Fever Dream’ Twinning With ‘80s Icon, 73, Onstage: ‘Such an Unexpected Duo’